Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA(R) (nusinersen) for Spinal Muscular Atrophy
(NASDAQ:BIIB),(NASDAQ:IONS), Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naive and previously-treated nusinersen patients with SMA1 Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people […]